Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/27/2025 | $3.50 | Overweight | Barclays |
| 5/14/2025 | $4.00 | Buy | H.C. Wainwright |
| 12/20/2024 | $12.00 → $15.00 | Buy | H.C. Wainwright |
| 12/11/2023 | $6.00 | Buy | H.C. Wainwright |
| 8/14/2023 | $2.75 → $3.50 | Underweight → Neutral | Piper Sandler |
| 6/22/2023 | $6.00 | Overweight | Cantor Fitzgerald |
| 5/16/2022 | $10.00 → $4.00 | Overweight → Underweight | Piper Sandler |
| 10/29/2021 | $17.00 | Outperform | Cowen & Co. |
- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results represent first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit - DURHAM, N.C., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of new, long-term data assessing the durability of Symvess in extremity arterial trauma
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, providing up to $77.5 million in principal amount of new financing. The credit agreement, which has a term of four years, includes an initial tranche of $40 million fully funded at close, and an additional two tranches of up to an aggregate of $37.5 million available to Humacyte, subject to the satisfaction of certain revenue, regulatory appro
– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – – Positive outcomes for dialysis patients suffering from Steal syndrome who were treated with the ATEV – – Additional presentations report durable two-year outcomes for patients treated in Ukraine conflict, superior two-year outcomes for female dialysis patients, and results for patients treated with torso arterial trauma – DURHAM, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioen
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
Barclays initiated coverage of Humacyte with a rating of Overweight and set a new price target of $3.50
H.C. Wainwright resumed coverage of Humacyte with a rating of Buy and set a new price target of $4.00
H.C. Wainwright reiterated coverage of Humacyte with a rating of Buy and set a new price target of $15.00 from $12.00 previously
8-K - Humacyte, Inc. (0001818382) (Filer)
424B5 - Humacyte, Inc. (0001818382) (Filer)
8-K - Humacyte, Inc. (0001818382) (Filer)
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
BioAesthetics Corporation announced today the appointment of Juliana Blum, PhD as its new Chief Executive Officer, effective August 12, 2024. Dr. Sandra Coufal, MD, Director of BioAesthetics and CEO of Toragen, Inc. said, "This is an important milestone for BioAesthetics. During the development of every successful biotech company, there comes a time when the founding CEO transitions to a different role and a new CEO with different skill sets is needed for product advancement and commercialization. Dr. Blum's experience with novel products as co-founder of Humacyte will help guide further progress at BioAesthetics." Dr. Blum joins BioAesthetics following her 20 years spent as Co-founder
DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors. "Diane is an innovator and strategist with extensive experience in the biopharmaceutical industry, and we are delighted to welcome her to the Humacyte board," said Kathleen Sebelius, Chair of Humacyte's board of directors. "Her expertise in guiding companies with innovative products to the market will be invaluable as Humacyte moves toward commercialization of the Human Acellular VesselTM (HAV). We al
--Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle-- --Key appointment as Humacyte advances HAV through multiple late-stage clinical trials in initial vascular applications-- DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Shamik J. Parikh, M.D., as Chief Medical Officer. In this role, Dr. Parikh will lead the company's global clinical development strategy, including oversight of the preclinical and clinical
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)
- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - - Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – - Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations - - Conference call today at 8:00 am ET - DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercia
DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended September 30, 2025, on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte Third Quarter 2025 Financial Results and Corporate UpdateDate:November 12, 2025Time:8:00 AM Eastern TimeConference Call Details:1-877-704-4453 (U.S. Investors Dial)1-201-389-0920 (International Investors Dial)13756236 (Conference ID)Call me™ Feature
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended June 30, 2025, on Monday, August 11, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte Second Quarter 2025 Financial Results and Corporate UpdateDate:August 11, 2025Time:8:00 AM Eastern TimeConference Call Details:1-877-704-4453 (U.S. Investors Dial)1-201-389-0920 (International Investors Dial)13754596 (Conference ID)Call meTM Feature: Click Here